Dow Down0.68% Nasdaq Down0.42%

More On HNCMF

Quotes

Charts

News & Info

Company

Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

Hutchison China MediTech Ltd. (HNCMF)

-Other OTC
13.95 0.00(0.00%) Aug 27
ProfileGet Profile for:
Hutchison China MediTech Ltd.
Hutchison House
22nd Floor
Hong Kong,
Hong Kong - Map
Phone: 852 2128 1188
Fax: 852 2128 1778
Website: http://www.chi-med.com

Details 
Index Membership:N/A
Sector:N/A
Industry:N/A
Full Time Employees:N/A

Business Summary 

Hutchison China MediTech Limited, together with its subsidiaries, is engaged in the research, development, manufacture, distribution, and sale of pharmaceuticals and health oriented consumer products. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including Volitinib, a c-Met inhibitor for oncology, which has completed Phase I clinical trials; and Fruquintinib, a vascular endothelial growth factor receptor inhibitor for oncology, which has completed Phase I clinical trials, as well as HMPL-004 that has completed Phase II clinical trials for ulcerative colitis and Crohn’s disease. Further, it develops Sulfatinib, Epitinib, and Theliatinib, which are under Phase I clinical trials for the treatment of tumor, as well as late-stage preclinical drug candidate HMPL-507, an inflammation target. Additionally, the company develops HMPL-523, a small molecule inhibitor target for Syk, and investigational therapies in immunology and oncology; and HMPL-453, a fibroblast growth factor receptor target in oncology. The company also offers organic and natural food, beverage, baby, and beauty care products; distributes organic and natural products; and sells non-organic health related consumer products. It operates primarily in the People’s Republic of China, the United Kingdom, France, and Hong Kong. The company has partnership agreements with Nestlé Health Science, Lilly, AstraZeneca, and Janssen. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Hutchison China MediTech Ltd.

Key Executives 
 PayExercised
Mr. Simon To BSc, ACGI, MBA, 62
Exec. Chairman, Chairman of Remuneration Committee, Member of Complaints Committee and Member of Technical Committee
20.00KN/A
Mr. Christian Hogg BSc,MBA, 48
Chief Exec. Officer, Exec. Director, Member of Complaints Committee and Member of Technical Committee
977.00KN/A
Mr. Chig Fung Cheng , 47
Chief Financial Officer and Exec. Director
486.00KN/A
Ms. Edith Shih BSE, MA, EdM, Solicitor, FCIS, FCS(PE), 62
Company Sec., Non-Exec. Director and Member of Complaints Committee
20.00KN/A
Mr. Michael Leung ,
Deputy Gen. Mang. of Bus. Devel.
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.